Clinical trial

Cannabinoids in PLWHIV on Effective ART

NCT03550352

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-08-20

PhasePHASE2

Study timeline

Study start (actual)2021-08-20Date precision: day

Registry last updated2022-06-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)DRUG

TN-C200M2 oral capsules (CBD 200 mg)DRUG

Sponsors & collaborators

McGill University Health Centre/Research Institute of the McGill University Health Centrelead sponsor

Tilraycollaborator

CIHR Canadian HIV Trials Networkcollaborator

Université du Québec a Montréalcollaborator

Centre de Recherche du Centre Hospitalier de l'Université de Montréalcollaborator

Mapped research locations

MontrealQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03550352 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.